Announcements Trials

Browse Landscape

Phase

Status

Terminated 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Leukemia, Myeloid, Acute 9 Myelodysplastic Syndromes 2 Leukemia, Myelomonocytic, Chronic 2 Sinonasal undifferentiated carcinoma 1 Neoplasms 1 Myeloproliferative Disorders 1 Lymphoma, T-Cell 1 Leukemia, Biphenotypic, Acute 1 Esthesioneuroblastoma, Olfactory 1 Chondrosarcoma 1 Anemia, Refractory, with Excess of Blasts 1

Interventions

Blood Specimen Collection 38 pembrolizumab 36 Bevacizumab 22 Surveys and Questionnaires 18 Standard of Care 18 Radiotherapy 18 Exercise 17 Carboplatin 16 Nivolumab 15 atezolizumab 14 Cisplatin 14 Drug Therapy 13 Paclitaxel 12 Fluorouracil 12 Cyclophosphamide 12 Cetuximab 12 Trastuzumab 10 Leucovorin 10 Docetaxel 10 Dexamethasone 10 Pemetrexed 9 Oxaliplatin 9 Biopsy 9 pertuzumab 8 olaparib 8 Temozolomide 8 Panitumumab 8 Observation 8 Irinotecan 8 abemaciclib 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Neoplasms × enasidenib × Clear all

NCT02813135 2026-01-16

ESMART

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡